- Home
- SBGI vs YDES Comparison
SBGI vs YDES Comparison
Compare SBGI & YDES Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SBGI | YDES |
|---|---|---|
| Founded | 1986 | 2013 |
| Country | United States | Taiwan |
| Employees | N/A | N/A |
| Industry | Broadcasting | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 894.2M |
| IPO Year | 1995 | N/A |
Fundamental Metrics
Financial Performance| Metric | SBGI | YDES |
|---|---|---|
| Price | $14.97 | $9.84 |
| Analyst Decision | Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $21.00 | N/A |
| AVG Volume (30 Days) | ★ 362.1K | 37.5K |
| Earning Date | 02-25-2026 | 03-30-2026 |
| Dividend Yield | ★ 6.68% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,337,000,000.00 | $510,360.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.28 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 45.76 |
| 52 Week Low | $11.89 | $5.30 |
| 52 Week High | $17.88 | $31.00 |
Technical Indicators
Market Signals| Indicator | SBGI | YDES |
|---|---|---|
| Relative Strength Index (RSI) | 52.83 | 35.00 |
| Support Level | $14.37 | $9.76 |
| Resistance Level | $15.30 | $11.80 |
| Average True Range (ATR) | 0.57 | 0.75 |
| MACD | 0.10 | -0.15 |
| Stochastic Oscillator | 82.34 | 3.09 |
Price Performance
Historical ComparisonAbout SBGI Sinclair Inc.
Sinclair Inc. is the owner-operator of the second largest portfolio of television stations in the United States, with 185 full power stations in 86 markets, covering 40% of US households. Of the firm's roughly 600 channels, 150 are affiliated with the four national broadcasters—Fox, ABC, CBS, and NBC—with over 80 other channels aligned with The CW (Nexstar) and MyNetworkTV (Fox). Sinclair owns the Tennis Channel and stakes in Marquee Sports Network and YES Network, providing their premium sports content to pay-TV distributors.
About YDES YD Bio Limited Ordinary Shares
YD Bio Ltd is a biopharmaceutical company focusing on blood-based cancer detection, the development of stem cell- and exosome-based therapeutics with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need and serving as a trusted supplier of clinical testing drugs for pharmaceutical companies. Stem cell therapy uses versatile cells to repair or regenerate damaged tissues, offering innovative treatments for injuries, degenerative diseases, and immune disorders with potential for personalized medicine and tissue engineering.